Recent

% | $
Quotes you view appear here for quick access.

Cyclacel Pharmaceuticals, Inc. Message Board

  • bluekat696 bluekat696 Dec 7, 2012 1:11 AM Flag

    Monday it's $5 or $15

    Do you wanna flip a coin?

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • There is no new data. Poster already out online. So what is there for flipping coin?

      • 2 Replies to a730556
      • The abstract online discusses the phase I/II data:

        "Here we report the pooled analysis of 46 patients who were treated in a phase I/II study (n=25) and the lead-in phase of the phase III study (n=21)....Conclusion: The sequential combination of decitabine and sapacitabine appears to be safe and active. A large randomized, phase III trial is currently underway comparing this treatment regimen against single agent decitabine in the treatment of elderly AML."

        During the convention, Cyclacel will be providing an update to the PIII trial, and the PIII update is not in this abstract. So the stock could be either $5 or $10 on Monday, depending on the data in the PIII update.

        Sentiment: Strong Buy

      • The abstract online discusses the P1/P2 data:

        "Here we report the pooled analysis of 46 patients who were treated in a phase I/II study (n=25) and the lead-in phase of the phase III study (n=21)....Conclusion: The sequential combination of decitabine and sapacitabine appears to be safe and active. A large randomized, phase III trial is currently underway comparing this treatment regimen against single agent decitabine in the treatment of elderly AML."

        During the convention, Cyclacel will be providing an update to the P3 trial and the P3 update is not in this abstract. So the stock could be either $5 or $10, depending on the data in the P3 update.

        Sentiment: Strong Buy

      • Wrong. The timeline will be revealed {KM curve}. The poster is only one piece of the info.

        Sentiment: Strong Buy

      • The abstract online discusses the P1/P2 data:

        "Here we report the pooled analysis of 46 patients who were treated in a phase I/II study (n=25) and the lead-in phase of the phase III study (n=21)....Conclusion: The sequential combination of decitabine and sapacitabine appears to be safe and active. A large randomized, phase III trial is currently underway comparing this treatment regimen against single agent decitabine in the treatment of elderly AML."

        During the convention, Cyclacel will be providing an update to the P3 trial (ie. SEAMLESS), and the P3 update is not in this abstract. So the stock could be either $5 or $10, depending on the data of the SEAMLESS update.

        Sentiment: Strong Buy

      • The abstract online discusses the P1/P2 data:

        "Here we report the pooled analysis of 46 patients who were treated in a phase I/II study (n=25) and the lead-in phase of the phase III study (n=21)....Conclusion: The sequential combination of decitabine and sapacitabine appears to be safe and active. A large randomized, phase III trial is currently underway comparing this treatment regimen against single agent decitabine in the treatment of elderly AML."

        During the convention, CYCC will be providing an update to the P3 trial (ie. SEAMLESS), and the P3 update is not in this abstract. So the stock could be either $5 or $10, depending on the data of the SEAMLESS update.

        Sentiment: Strong Buy

      • The abstract online discusses the P1/P2 data:

        "Here we report the pooled analysis of 46 patients who were treated in a phase I/II study (n=25) and the lead-in phase of the phase III study (n=21)....Conclusion: The sequential combination of decitabine and sapacitabine appears to be safe and active. A large randomized, phase III trial is currently underway comparing this treatment regimen against single agent decitabine in the treatment of elderly AML."

        During the convention, CYCC will be providing an update to the P3 trial (ie. SEAMLESS), and the P3 update is not in this abstract. So the stock could be either $5 or $10, depending on the data of the SEAMLESS update.

        Sentiment: Strong Buy

 
CYCC
0.39-0.03(-7.14%)Apr 29 3:58 PMEDT